MV analysis for B-cell reconstitution 2 to 5 years after non-MSD HCT
| Variable and categories . | N (N event)* . | HR estimate (95% CI)† . | P . | Overall P‡ . |
|---|---|---|---|---|
| Conditioning | ||||
| No/IS (baseline) | 189 (57) | 1.00 | <.001 | |
| RIC/MAC | 86 (60) | 5.39 (2.74-10.61) | <.001 | |
| Donor type | ||||
| MMRD (baseline) | 203 (66) | 1.00 | <.001 | |
| MORD | 17 (11) | 5.56 (1.64-18.83) | .006 | |
| URD | 55 (40) | 3.46 (1.56-7.65) | .002 | |
| Genotype | ||||
| IL2RG/JAK3 (baseline) | 127 (39) | 1.00 | <.001 | |
| IL7R, CD3 (any), CD45 | 24 (15) | 6.78 (2.54-18.07) | <.001 | |
| ADA | 14 (9) | 4.55 (1.26-16.49) | .021 | |
| DCLRE1C | 11 (2) | 0.32 (0.05-1.96) | .218 | |
| RAG | 16 (6) | 0.29 (0.06-1.30) | .105 | |
| Other/unknown/ND | 83 (46) | 2.04 (1.05-3.97) | .036 | |
| Stratum | ||||
| A (baseline) | 252 (102) | 1.00 | .393 | |
| B | 23 (15) | 1.73 (0.49-6.04) | .393 |
| Variable and categories . | N (N event)* . | HR estimate (95% CI)† . | P . | Overall P‡ . |
|---|---|---|---|---|
| Conditioning | ||||
| No/IS (baseline) | 189 (57) | 1.00 | <.001 | |
| RIC/MAC | 86 (60) | 5.39 (2.74-10.61) | <.001 | |
| Donor type | ||||
| MMRD (baseline) | 203 (66) | 1.00 | <.001 | |
| MORD | 17 (11) | 5.56 (1.64-18.83) | .006 | |
| URD | 55 (40) | 3.46 (1.56-7.65) | .002 | |
| Genotype | ||||
| IL2RG/JAK3 (baseline) | 127 (39) | 1.00 | <.001 | |
| IL7R, CD3 (any), CD45 | 24 (15) | 6.78 (2.54-18.07) | <.001 | |
| ADA | 14 (9) | 4.55 (1.26-16.49) | .021 | |
| DCLRE1C | 11 (2) | 0.32 (0.05-1.96) | .218 | |
| RAG | 16 (6) | 0.29 (0.06-1.30) | .105 | |
| Other/unknown/ND | 83 (46) | 2.04 (1.05-3.97) | .036 | |
| Stratum | ||||
| A (baseline) | 252 (102) | 1.00 | .393 | |
| B | 23 (15) | 1.73 (0.49-6.04) | .393 |
For each “variable,” the categories are compared with the “baseline” reference group. The P values displayed for the individual categories of a variable help to assess the relative evidence of effect among the individual categories, relative to each other, but cannot be interpreted as common P values. The “HR” characterizes the ratio in instantaneous chance of B-cell reconstitution relative to the reference group. Other statistically significant pairwise comparisons include ADA vs DCLRE1C: HR, 14.21 (95% CI, 1.66-121.27), P = .015; ADA vs RAG: HR, 15.92 (95% CI, 2.46-102.93), P = .004; DLCRE1C vs IL7R-CD3-CD45: HR, 0.05 (95% CI, 0.01-0.35), P = .003; DLCRE1C vs Other/unknown/ND: HR, 0.16 (95% CI, 0.03-0.98), P =.048; IL7R-CD3-CD45 vs RAG: HR, 23.72 (95% CI, 4.13-136.40), P < .001; IL7R-CD3-CD45 vs Other/unknown/ND: HR, 3.33 (95% CI, 1.19-9.27), P = .021; and Other/unknown/ND vs RAG: HR, 7.13 (95% CI, 1.62-31.46), P = .01.
ND, not done.
“N” is the number of subjects in the category of the variable; the “N event” is B-cell reconstitution during 2 to 5 y after HCT, defined as being off intravenous Ig.
The “HR estimate” is for the event of B-cell reconstitution.
“Overall P” provides the overall significance of the variable in the model.